Acme United Corporation. (ACU)

On our desk, ACU has been an incredible outperformer, jumping nearly 48.7% since early May. The recent Q2 2026 results were undeniably strong, with EPS coming in at $1.22 and sales up 16% year-over-year, heavily supported by the MyMedic acquisition and world-class pricing strategies. However, given that valuation multiples have normalized and the stock has run up significantly to around $62.10, a prudent downgrade to 'Hold' makes a lot of sense from a risk-reward perspective.

Looking at the balance sheet and quarterly cadence, I see some emerging friction points. While the multi-month rally is impressive, the company ended the latest quarter with $27.3 million in net debt. Furthermore, we cannot ignore the volatility demonstrated earlier in the year when Q1 2026 EPS missed consensus estimates by over 50%. Investors need to carefully weigh whether organic growth and pricing power can sustain this leverage profile moving forward.

When evaluating ACU's operational metrics, our quant models show a fascinating interplay between technical support levels and fundamental catalysts. The stock has repeatedly tested and bounced off established support lines before major rallies, such as its 14% surge past $49.83. Analysts must closely monitor short interest—currently sitting at a modest 1.62%—alongside trailing P/E multiples around 25.60 to time potential consolidation entries accurately.